Buruli-RifDACC: Evaluation of the efficacy and cost-effectiveness of high-dose versus standard-dose rifampicin on outcomes in Mycobacterium ulcerans disease, a protocol for a randomised controlled trial in Ghana [version 1; peer review: 2 approved]

Buruli-RifDACC: Evaluation of the efficacy and cost-effectiveness of high-dose versus standard-dose rifampicin on outcomes in Mycobacterium ulcerans disease, a protocol for a randomised controlled trial in Ghana [version 1; peer review: 2 approved]

Background: Buruli ulcer (BU) can lead to disfiguring ulcers and permanent disability. The 2030 World Health Organization (WHO) road map for Neglected Tropical Diseases (NTDs) calls for major scaling up in diagnosis and management to eliminate disability due to the disease. Current treatment for BU...

Full description

Bibliographic Details
Main Authors: Abigail Agbanyo, Yaw Ampem Amoako, Lucy Owusu, Jacob Novignon, Adwoa Asante-Poku, Joseph Tuffour, Iris Mosweu, Yohannes Hailemichael, Charles Opondo, Ruth Canter, Catherine Pitt, Elizabeth Allen, Stephen L. Walker, Dorothy Yeboah-Manu, Richard Odame Phillips, Michael Marks
Format: Article
Language:English
Published: F1000 Research Ltd 2022-11-01
Series:NIHR Open Research
Subjects:
Buruli ulcer
Randomised Controlled Trial
High Dose Rifampicin
DACC
cost-effectiveness
eng
Online Access:https://openresearch.nihr.ac.uk/articles/2-59/v1

Internet

https://openresearch.nihr.ac.uk/articles/2-59/v1

Similar Items